NASDAQ:PHVS Pharvaris Q4 2024 Earnings Results & Report $33.27 -0.56 (-1.65%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more. Pharvaris beat analyst earnings expectations in its Q4 2024 results, released April 7, 2025. The company reported EPS of -$0.68 versus the -$0.74 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateApril 7, 2025TimeBefore Market OpensConference Call DateApril 6, 2025Conference Call6:00 PM ET Pharvaris EPS ResultsActual EPS-$0.68Consensus EPS -$0.74Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersPharvaris Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual Report(20-F) Pharvaris Q4 2024 Earnings FAQ Did Pharvaris beat earnings estimates for Q4 2024? Pharvaris (NASDAQ:PHVS) reported earnings of -$0.68 per share for Q4 2024, beating the consensus estimate of -$0.74. The report was announced on Monday, April 7, 2025. Pharvaris Earnings HeadlinesPharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific MeetingNovember 12 at 10:28 AM | globenewswire.comPharvaris Q3 2026: Wider Loss as FDA Decision NearsNovember 12 at 8:38 AM | 247wallst.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 13 at 1:00 AM | Traders Agency (Ad)Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12 at 6:50 AM | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Immunocore Holdings (IMCR), Pharvaris (PHVS) and Moderna (MRNA)November 10 at 2:49 PM | theglobeandmail.comPharvaris (PHVS) Expected to Post Quarterly Earnings on WednesdayNovember 10 at 3:11 AM | americanbankingnews.comSee More Pharvaris Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email. Email Address About PharvarisPharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks. Pharvaris does not have a marketed product; its work centers on research and clinical development. Its programs are intended to offer an oral alternative to existing HAE treatments, many of which are administered by injection.View Pharvaris ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense OpportunityThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid? Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
